Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients

Recruiting now · Not applicable

Conditions studied: Lung Cancer, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Metastatic Lung Cancer

In brief

In clinical trials, patients are selected according to strict eligibility criteria (inclusion and exclusion criteria). These criteria aim to ensure homogeneity within the trial population, but may omit patients with specific characteristics, comorbidities or co-medications. Indeed, patients of advanced age, with comorbidities or brain metastases, who are frequently encountered in clinical practice, are often excluded from clinical trials. Real-life data in oncology play a vital role in assessing the efficacy of therapies and therapeutic strategies, complementing data from controlled clinical trials. They make it possible to analyze a larger population and take into account multiple variables such as patient history, co-medications and comorbidities, but also to analyze efficacy and toxicity data in populations not represented in clinical trials. The establishment of a prospective cohort including various stages and histologies will make it possible to set up a platform of available data, including a maximum of data linked to the patient, his tumor and his treatments, collected longitudinally until the patient's death (or the end of the study). In parallel with this cohort, the project aims to set up a longitudinal plasmatheque (from diagnosis to death, or at the end of the study), as well as a tumorotheque (samples systematically stored as part of care by the CHU tumorotheque, and for which patient consent allows their use in research depending on the material available) for patients with available tumor samples. This will enable the construction of ancillary projects to validate research hypotheses, for example concerning the identification of mechanisms of resistance to therapies.

Key facts

Study ID: NCT06481813
Run by: Nantes University Hospital
People needed: 730
Starts: 2024-12-10
Expected to finish: 2034-12-01
Last updated by the study team: 2026-01-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Patients :
Adult
Patient newly diagnosed with NSCLC or CPC
Cared for at Nantes University Hospital
Affiliated or beneficiaries of a social security scheme or similar
Treated with a systemic therapy including chemotherapy and/or immunotherapy and/or targeted therapy and/or therapy as part of a clinical trial after agreement from the sponsors of the studies concerned (only in the absence of blinding).
Having agreed to participate in this study by signing the biocollection consent.
Healthy subjects :
Adult
Affiliated or beneficiaries of a social security or similar scheme
Who have agreed to participate in this study by signing the Biocollection consent form.
No known infectious pathology
No known history of cancer
No known history of chronic autoimmune disease
No background immuno-suppressive treatment
Ancillary Study :
Metastatic NSCLC with a KRAS G12C mutation, receiving treatment with Sotorasib, Adagrasib, or another KRAS G12C inhibitor, either as monotherapy or in combination.

You may not qualify if…

Patients :
Previous anticancer treatment for Lung cancer
Patients who have not consented to participate in the BREATHE collection
History of cancer (excluding thoracic cancer) with evidence of disease for less than 2 years
Inclusion in a therapeutic trial with blinded treatment
Patients under guardianship
Patients with AME.
Pregnant or breast-feeding women
Healthy subjects :
Person under guardianship
Person benefiting from AME (State medical aid)
Pregnant or breast-feeding women
Ancillary Study :
Pregnant or breast-feeding women

Where it is running

CHU Nantes — Nantes, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.